Aprea Therapeutics

Historical price data

Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, selective DNA Damage Response (DDR) inhibitors for cancer. Its strategy leverages the principle of synthetic lethality, aiming to selectively kill cancer cells with specific genetic defects while sparing healthy tissue. The company's near-term value is driven by two clinical-stage assets: APR-1051, a next-generation WEE1 inhibitor, and ATRN-119, a macrocyclic ATR inhibitor, both with key clinical readouts anticipated in 2026. Aprea's mission is to translate foundational academic research into transformative therapies for patients with limited treatment options.

A platform for developing selective small molecule inhibitors targeting DNA Damage Response (DDR) pathways, leveraging synthetic lethality to exploit cancer-specific genetic vulnerabilities for a wider therapeutic window.

Aprea faces formidable competition in both the WEE1 (e.g., Zentalis' adavosertib) and ATR (e.g., Bayer's elimusertib) inhibitor spaces from companies with more advanced clinical programs and greater resources. Its competitive angle hinges solely on demonstrating superior selectivity/tolerability with APR-1051 and identifying a high-value combination niche for ATRN-119.